Docket #: S12-173
Disulfide-linked Foldon Domains To Stabilize Protein Trimers
Researchers in Dr. James Swartz's lab have developed foldon domains that can be used to stabilize protein trimers even under stressful conditions that would otherwise disassemble the trimeric structure. The ability to trimerize proteins is of great interest for biomaterial applications, such as vaccine development. Proteins such as influenza hemagglutinin naturally form trimeric structures. When used as vaccines, such trimers may disassemble before the vaccine can be administered. This technology overcomes this limitation by providing stable covalent bonds between the monomers of trimeric protein structures without affecting the conformation of the trimeric protein.
Stage of Research
The inventors have optimized the foldon monomer and folding conditions. In addition, when used with a hemagglutinin stem domain protein the correct immunogenic conformation of this stabilized HA stem trimer was obtained and confirmed.
Applications
- Vaccines
- Therapeutics
- Materials that require a trimeric protein structure
Advantages
- Stabilizes trimeric structures
- Does not affect the conformation of the trimeric protein
- Can be fused to any protein partner
- Can be C-terminal or N-terminal to the fusion partner
- Ensures high quality final protein product
- Facilitates the manufacture of trimeric protein products
Related Links
Patents
- Published Application: WO2013042229
- Published Application: 20150141616
Similar Technologies
-
System biological analysis of vaccination for mechanisms of adjuvanticity and antibody durability in humans S21-012System biological analysis of vaccination for mechanisms of adjuvanticity and antibody durability in humans
-
Enhanced activation of CD8+ and CD4+ T cells by a vaccine targeting CD244 or CD48 S20-039Enhanced activation of CD8+ and CD4+ T cells by a vaccine targeting CD244 or CD48
-
Eterna Enterprise: A Secure Platform for Designing Enhanced mRNA Vaccines S20-217Eterna Enterprise: A Secure Platform for Designing Enhanced mRNA Vaccines